Literature DB >> 4358147

Histopathology of tumor regression after intralesional injection of Mycobacterium bovis. IV. Development of immunity to tumor cells and BCG.

M G Hanna, M J Snodgrass, B Zbar, H J Rapp.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1973        PMID： 4358147     DOI： 10.1093/jnci/51.6.1897

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN： 0027-8874            Impact factor:   13.506


× No keyword cloud information.
  13 in total

Review 1.  The role of immunotherapy in the management of patients with malignant melanoma.

Authors:  J E Goodnight; D L Morton
Journal:  World J Surg       Date:  1979-07-30       Impact factor: 3.352

2.  Failure of BCG immunostimulation to affect the clinical course of Burkitt's lymphoma.

Authors:  I T Magrath; J L Ziegler
Journal:  Br Med J       Date:  1976-03-13

Review 3.  Modulation of antitumor immunity--immunobiologic approaches.

Authors:  R J North; E S Dye; C D Mills; J P Chandler
Journal:  Springer Semin Immunopathol       Date:  1982

4.  Induction of urinary interleukin-1 (IL-1), IL-2, IL-6, and tumour necrosis factor during intravesical immunotherapy with bacillus Calmette-Guérin in superficial bladder cancer.

Authors:  E C De Boer; W H De Jong; P A Steerenberg; L A Aarden; E Tetteroo; E R De Groot; A P Van der Meijden; P D Vegt; F M Debruyne; E J Ruitenberg
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

5.  Macrophages and resistance to tumours. I. Inhibition of delayed-type hypersensitivity reactions by tumour cells and by soluble prducts affecting macrophages.

Authors:  M Nelson; D S Nelson
Journal:  Immunology       Date:  1978-02       Impact factor: 7.397

6.  Effects of isoniazid (INH) on the BCG-induced local immune response after intravesical BCG therapy for superficial bladder cancer.

Authors:  M J Stassar; P D Vegt; P A Steerenberg; A P van der Meijden; H D Meiring; M Dessens-Kroon; H G Geertzen; W den Otter
Journal:  Urol Res       Date:  1994

7.  Tumour rejection in immunized guinea-pigs.

Authors:  A Kolin; J Vacek; S Landi
Journal:  Br J Exp Pathol       Date:  1983-10

8.  Immunological aspects of intravesical administration of Bacillus Calmette-Guérin (BCG) in the guinea pig.

Authors:  A P van der Meijden; W H de Jong; E C de Boer; P A Steerenberg; F M Debruyne; E J Ruitenberg
Journal:  Urol Res       Date:  1989

9.  Presence of activated lymphocytes in the urine of patients with superficial bladder cancer after intravesical immunotherapy with bacillus Calmette-Guérin.

Authors:  E C De Boer; W H De Jong; A P Van Der Meijden; P A Steerenberg; J A Witjes; P D Vegt; F M Debruyne; E J Ruitenberg
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

10.  Antitumor activity of mycobacterial glycolipid A1.

Authors:  Z Reggiardo
Journal:  Infect Immun       Date:  1978-09       Impact factor: 3.441
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.